Amarin_Logo_JPEG.jpg
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology’s 70th Annual Scientific Session
May 15, 2021 08:00 ET | Amarin Corporation plc
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher...
Amarin_Logo_JPEG.jpg
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session
May 04, 2021 07:00 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new clinical data and other research results regarding VASCEPA®...
Amarin_Logo_JPEG.jpg
Amarin Reports First Quarter 2021 Financial Results and Provides Business Update
April 29, 2021 06:10 ET | Amarin Corporation plc
Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19...
Amarin_Logo_JPEG.jpg
Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel
April 29, 2021 06:00 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that Joseph T. Kennedy has informed the board of directors of his...
Amarin_Logo_JPEG.jpg
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
April 22, 2021 10:53 ET | Amarin Corporation plc
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication1,2,3 VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization...
Amarin_Logo_JPEG.jpg
Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021
April 20, 2021 06:05 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior...
Amarin_Logo_JPEG.jpg
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
April 17, 2021 09:50 ET | Amarin Corporation plc
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect on coronary plaque stabilization reported to be significant...
Amarin_Logo_JPEG.jpg
Amarin Announces CEO Succession Plan
April 12, 2021 16:30 ET | Amarin Corporation plc
John Thero to Retire as President and CEO on August 1, 2021 Board Appoints Karim Mikhail, Current SVP and Head of Commercial for Europe, as Successor DUBLIN, Ireland and BRIDGEWATER, N.J., April ...
Amarin_Logo_JPEG.jpg
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
April 06, 2021 06:05 ET | Amarin Corporation plc
Reimbursement dossiers for first 10 countries to be filed in coming months 150 people hired and on-track to be deployed by mid-Q2 2021 supplemented by digital outreach and medical education programs...
Amarin_Logo_JPEG.jpg
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
March 30, 2021 06:24 ET | Amarin Corporation plc
Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other risk characteristics as...